Reconsidering dietary polyunsaturated fatty acids in bipolar disorder: A translational picture

Journal of Clinical Psychiatry

Volumn 77, Issue 10, 2016, Pages e1342-e1347

  Saunders, Erika F H ^a,b   Ramsden, Christopher E ^c   Sherazy, Mostafa S ^a   Gelenberg, Alan J ^a   Davis, John M ^d   Rapoport, Stanley I ^e  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CARBAMAZEPINE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; FLUOXETINE; GAMMA INTERFERON; LAMOTRIGINE; LINOLEIC ACID; LITHIUM; TUMOR NECROSIS FACTOR; VALPROIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; TRANQUILIZER;

BIPOLAR DISORDER; COMORBIDITY; DIETARY INTAKE; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; FATTY ACID METABOLISM; GENETIC TRANSCRIPTION; HUMAN; META ANALYSIS (TOPIC); MIGRAINE; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMISSION; NONHUMAN; OPEN STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME; UPREGULATION; ANIMAL; BRAIN; COMBINATION DRUG THERAPY; DRUG EFFECTS; METABOLISM; PSYCHOLOGY; RAT;

ANIMALS; ANTIMANIC AGENTS; ARACHIDONIC ACID; BIPOLAR DISORDER; BRAIN; DOCOSAHEXAENOIC ACIDS; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; HUMANS; RATS;

EID: 84992735227     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.15com10431     Document Type: Review

References (103)

1. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd ed. New York, NY: Oxford University Press; 2007.
2. Ng F, Mammen OK, Wilting I, et al; International Society for Bipolar Disorders. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11(6):559-595. doi:10.1/j.139-5618.209.0737.x PubMed
3. Rapoport SI. Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade. ACS Chem Neurosci. 2014;5(6):459-467. doi:10.1021/cn5058v PubMed
4. Rapoport SI, Basselin M, Kim HW, et al. Bipolar disorder and mechanisms of action of mood stabilizers. Brain Res Brain Res Rev. 2009;61(2):185-209. doi:10.1016/j.brainresrev.209.06.03 PubMed
5. Rapoport SI, Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry. 2002;59(7):592-596. doi:10.101/archpsyc.59.7.592 PubMed
6. Hibbeln JR, Palmer JW, Davis JM. Are disturbances in lipid-protein interactions by phospholipase-A2 a predisposing factor in affective illness? Biol Psychiatry. 1989;25(7):945-961. doi:10.1016/06-323(89)90274-6 PubMed
7. Allison JH, Stewart MA. Reduced brain inositol in lithium-treated rats. Nat New Biol. 1971;233(43):267-268. doi:10.1038/newbio23267a0 PubMed
8. Svennerholm L. Distribution and fatty acid composition of phosphoglycerides in normal human brain. J Lipid Res. 1968;9(5):570-579. PubMed
9. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001;294(5548):1871-1875. doi:10.126/science.294.548.1871 PubMed
10. Hickie I, Lloyd A. Are cytokines associated with neuropsychiatric syndromes in humans? Int J Immunopharmacol. 1995;17(8):677-683. doi:10.1016/0192-0561(95)054-6 PubMed
11. Dantzer R, Bluthé RM, Gheusi G, et al. Molecular basis of sickness behavior. Ann N Y Acad Sci. 1998;856(1 MOLECULAR MEC):132-138. doi:10.1/j.1749-632.198.tb08321.x PubMed
12. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2007;21(2):153-160. doi:10.1016/j.bi.206.09.06 PubMed
13. Parsadaniantz SM, Lebeau A, Duval P, et al. Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the activation of the hypothalamic-pituitary-Adrenal axis induced by interleukin-1beta in the male Rat. J Neuroendocrinol. 2000;12(8):766-773. doi:10.1046/j.1365-2826.20.0517.x PubMed
14. Navarra P, Tsagarakis S, Faria MS, et al. Interleukins-1 and-6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology. 1991;128(1):37-44. doi:10.1210/endo-128-1-37 PubMed
15. Serhan CN, Arita M, Hong S, et al. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids. 2004;39(11):1125-1132. doi:10.107/s1745-04-139-7 PubMed
16. Nye EJ, Hockings GI, Grice JE, et al. Aspirin inhibits vasopressin-induced hypothalamicpituitary-Adrenal activity in normal humans. J Clin Endocrinol Metab. 1997;82(3):812-817. PubMed
17. Blanchard HC, Taha AY, Rapoport SI, et al. Low-dose aspirin (acetylsalicylate) prevents increases in brain PGE2, 15-epi-lipoxin A4 and 8-isoprostane concentrations in 9 month-old HIV-1 transgenic rats, a model for HIV-1 associated neurocognitive disorders. Prostaglandins Leukot Essent Fatty Acids. 2015;96:25-30. doi:10.1016/j.plefa.2015.01.02 PubMed
18. Dawson E, Parfitt E, Roberts Q, et al. Linkage studies of bipolar disorder in the region of the Darier's disease gene on chromosome 12q23-24.1. Am J Med Genet. 1995;60(2):94-102. doi:10.102/ajmg.132060203 PubMed
19. Dawson E, Gill M, Curtis D, et al. Genetic association between alleles of pancreatic phospholipase A2 gene and bipolar affective disorder. Psychiatr Genet. 1995;5(4):177-180. doi:10.1097/0414-195240-05 PubMed
20. Jacobsen N, Daniels J, Moorhead S, et al. Association study of bipolar disorder at the phospholipase A2 gene (PLA2A) in the Darier's disease (DAR) region of chromosome 12q23-q24.1. Psychiatr Genet. 1996;6(4):195-199. doi:10.1097/0414-196240-05 PubMed
21. Jacobsen NJ, Franks EK, Owen MJ, et al. Mutational analysis of phospholipase A2A: a positional candidate susceptibility gene for bipolar disorder. Mol Psychiatry. 1999;4(3):274-279. doi:10.1038/sj.mp.40476 PubMed
22. Meira-Lima I, Jardim D, Junqueira R, et al. Allelic association study between phospholipase A2 genes and bipolar affective disorder. Bipolar Disord. 2003;5(4):295-299. doi:10.1034/j.139-5618.203.025.x PubMed
23. Dikeos DG, Papadimitriou GN, Souery D, et al. Lack of genetic association between the phospholipase A2 gene and bipolar mood disorder in a European multicentre casecontrol study. Psychiatr Genet. 2006;16(4):169-171. doi:10.1097/01.ypg.0218615.19892.86 PubMed
24. Noponen M, Sanfilipo M, Samanich K, et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry. 1993;34(9):641-649. doi:10.1016/06-323(93)90157-9 PubMed
25. Ross BM, Hughes B, Kish SJ, et al. Serum calcium-independent phospholipase A2 activity in bipolar affective disorder. Bipolar Disord. 2006;8(3):265-270. doi:10.1/j.139-5618.206.029.x PubMed
26. Ikenaga EH, Talib LL, Ferreira AS, et al. Reduced activities of phospholipases A2 in platelets of drug-naive bipolar disorder patients. Bipolar Disord. 2015;17(1):97-101. doi:10.1/bdi.129 PubMed
27. Kim HW, Rapoport SI, Rao JS. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol Psychiatry. 2011;16(4):419-428. doi:10.1038/mp.209.137 PubMed
28. Lee HJ, Rao JS, Chang L, et al. Chronic N-methyl-d-Aspartate administration increases the turnover of arachidonic acid within brain phospholipids of the unanesthetized rat. J Lipid Res. 2008;49(1):162-168. doi:10.194/jlr.M70406-JLR20 PubMed
29. Rao JS, Ertley RN, Rapoport SI, et al. Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2. J Neurochem. 2007;102(6):1918-1927. doi:10.1/j.1471-4159.207.04648.x PubMed
30. Kim HW, Rapoport SI, Rao JS. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis. 2010;37(3):596-603. doi:10.1016/j.nbd.209.1.010 PubMed
31. Brock TG. Arachidonic acid binds 14-3-3zeta, releases 14-3-3zeta from phosphorylated BAD and induces aggregation of 14-3-3zeta. Neurochem Res. 2008;33(5):801-807. doi:10.107/s1064-07-9498-3 PubMed
32. Rao JS, Harry GJ, Rapoport SI, et al. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15(4):384-392. doi:10.1038/mp.209.47 PubMed
33. Saunders EFH, Ramsden CE, Sherazy MS, et al. Omega-3 and omega-6 polyunsaturated fatty acids in bipolar disorder: a review of biomarker and treatment studies. J Clin Psychiatry. 2016;77(10):e1301-e1308.
34. Saunders EF, Reider A, Singh G, et al. Low unesterified:esterified eicosapentaenoic acid (EPA) plasma concentration ratio is associated with bipolar disorder episodes, and omega-3 plasma concentrations are altered by treatment. Bipolar Disord. 2015;17(7):729-742. doi:10.1/bdi.1237 PubMed
35. Chiu CC, Huang SY, Su KP, et al. Polyunsaturated fatty acid deficit in patients with bipolar mania. Eur Neuropsychopharmacol. 2003;13(2):99-103. doi:10.1016/S0924-97X(02)0130-X PubMed
36. Sublette ME, Bosetti F, DeMar JC, et al. Plasma free polyunsaturated fatty acid levels are associated with symptom severity in acute mania. Bipolar Disord. 2007;9(7):759-765. doi:10.1/j.139-5618.207.0387.x PubMed
37. Clayton EH, Hanstock TL, Hirneth SJ, et al. Long-chain omega-3 polyunsaturated fatty acids in the blood of children and adolescents with juvenile bipolar disorder. Lipids. 2008;43(11):1031-1038. doi:10.107/s1745-08-324-z PubMed
38. McNamara RK, Jandacek R, Rider T, et al. Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. J Affect Disord. 2010;126(1-2):303-311. doi:10.1016/j.jad.2010.03.015 PubMed
39. Evans SJ, Kamali M, Prossin AR, et al. Association of plasma ?-3 and ?-6 lipids with burden of disease measures in bipolar subjects. J Psychiatr Res. 2012;46(11):1435-1441. doi:10.1016/j.jpsychires.2012.07.016 PubMed
40. Pomponi M, Janiri L, La Torre G, et al. Plasma levels of n-3 fatty acids in bipolar patients: deficit restricted to DHA. J Psychiatr Res. 2013;47(3):337-342. doi:10.1016/j.jpsychires.2012.1.04 PubMed
41. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804-817. doi:10.1016/j.neubiorev.2010.10.01 PubMed
42. Vederman AC, Weisenbach SL, Rapport LJ, et al. Modality-specific alterations in the perception of emotional stimuli in bipolar disorder compared to healthy controls and major depressive disorder. Cortex. 2012;48(8):1027-1034. doi:10.1016/j.cortex.201.03.017 PubMed
43. Ryan KA, Vederman AC, McFadden EM, et al. Differential executive functioning performance by phase of bipolar disorder. Bipolar Disord. 2012;14(5):527-536. doi:10.1/j.139-5618.2012.01032.x PubMed
44. Langenecker SA, Saunders EF, Kade AM, et al. Intermediate: cognitive phenotypes in bipolar disorder. J Affect Disord. 2010;122(3):285-293. doi:10.1016/j.jad.209.08.018 PubMed
45. Haarman BC, Riemersma-Van der Lek RF, Burger H, et al. Relationship between clinical features and inflammation-related monocyte gene expression in bipolar disorder-towards a better understanding of psychoimmunological interactions. Bipolar Disord. 2014;16(2):137-150. doi:10.1/bdi.12142 PubMed
46. Becking K, Boschloo L, Vogelzangs N, et al. The association between immune activation and manic symptoms in patients with a depressive disorder. Transl Psychiatr. 2013;3(10):e314. doi:10.1038/tp.2013.87 PubMed
47. Bora E, Yücel M, Pantelis C, et al. Meta-Analytic review of neurocognition in bipolar II disorder. Acta Psychiatr Scand. 2011;123(3):165-174. doi:10.1/j.160-047.2010.01638.x PubMed
48. DelBello MP, Strakowski SM, Zimmerman ME, et al. MRI analysis of the cerebellum in bipolar disorder: a pilot study. Neuropsychopharmacology. 1999;21(1):63-68. doi:10.1016/S0893-13X(9)026-3 PubMed
49. Lyoo IK, Sung YH, Dager SR, et al. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord. 2006;8(1):65-74. doi:10.1/j.139-5618.206.0284.x PubMed
50. Savitz J, Frank MB, Victor T, et al. Inflammation and neurological disease-related genes are differentially expressed in depressed patients with mood disorders and correlate with morphometric and functional imaging abnormalities. Brain Behav Immun. 2013;31:161-171. doi:10.1016/j.bi.2012.10.07 PubMed
51. Savitz J, Dantzer R, Wurfel BE, et al. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. Psychoneuroendocrinology. 2015;52:200-211. doi:10.1016/j.psyneuen.2014.1.015 PubMed
52. Haarman BC, Burger H, Doorduin J, et al. Volume, metabolites and neuroinflammation of the hippocampus in bipolar disorder-A combined magnetic resonance imaging and positron emission tomography study. Brain Behav Immun. 2016;56:21-33. doi:10.1016/j.bi.2015.09.04 PubMed
53. Garrido R, Springer JE, Hennig B, et al. Apoptosis of spinal cord neurons by preventing depletion nicotine attenuates arachidonic acid-induced of neurotrophic factors. J Neurotrauma. 2003;20(11):1201-1213. doi:10.1089/089715032584628 PubMed
54. Chang MC, Bell JM, Purdon AD, et al. Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment. Neurochem Res. 1999;24(3):399-406. doi:10.1023/A:102098970130 PubMed
55. Bazinet RP, Weis MT, Rapoport SI, et al. Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder. Psychopharmacology (Berl). 2006;184(1):122-129. doi:10.107/s0213-05-0272-4 PubMed
56. Bazinet RP, Rao JS, Chang L, et al. Chronic carbamazepine decreases the incorporation rate and turnover of arachidonic acid but not docosahexaenoic acid in brain phospholipids of the unanesthetized rat: relevance to bipolar disorder. Biol Psychiatry. 2006;59(5):401-407. doi:10.1016/j.biopsych.205.07.024 PubMed
57. Lee HJ, Ertley RN, Rapoport SI, et al. Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex. Neurochem Res. 2008;33(5):861-866. doi:10.107/s1064-07-9526-3 PubMed
58. Lee HJ, Ghelardoni S, Chang L, et al. Topiramate does not alter the kinetics of arachidonic or docosahexaenoic acid in brain phospholipids of the unanesthetized rat. Neurochem Res. 2005;30(5):677-683. doi:10.107/s1064-05-2756-3 PubMed
59. Ghelardoni S, Bazinet RP, Rapoport SI, et al. Topiramate does not alter expression in rat brain of enzymes of arachidonic acid metabolism. Psychopharmacology (Berl). 2005;180(3):523-529. doi:10.107/s0213-05-2189-3 PubMed
60. Reese EA, Cheon Y, Ramadan E, et al. Gabapentin's minimal action on markers of rat brain arachidonic acid metabolism agrees with its inefficacy against bipolar disorder. Prostaglandins Leukot Essent Fatty Acids. 2012;87(2-3):71-77. doi:10.1016/j.plefa.2012.06.03 PubMed
61. Stolk P, Souverein PC, Wilting I, et al. Is aspirin useful in patients on lithium? a pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids. 2010;82(1):9-14. doi:10.1016/j.plefa.209.10.07 PubMed
62. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a doubleblind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23(2):87-94. doi:10.102/hup.912 PubMed
63. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170(11):1249-1262. doi:10.176/api.ajp.2013.13020185 PubMed
64. Lee HJ, Rao JS, Chang L, et al. Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder? Mol Psychiatry. 2010;15(6):602-614. doi:10.1038/mp.208.17 PubMed
65. Rao JS, Ertley RN, Lee HJ, et al. Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex. Pharmacogenomics J. 2006;6(6):413-420. doi:10.1038/sj.tpj.650391 PubMed
66. Edwards SJ, Hamilton V, Nherera L, et al. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation. Health Technol Assess. 2013;17(54):1-190. doi:10.310/hta17540 PubMed
67. Warner-Schmidt JL, Vanover KE, Chen EY, et al. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A. 2011;108(22):9262-9267. doi:10.1073/pnas.104836108 PubMed
68. Su KP, Lai HC, Yang HT, et al. Omega-3 fatty acids in the prevention of interferon-Alphainduced depression: results from a randomized, controlled trial. Biol Psychiatry. 2014;76(7):559-566. doi:10.1016/j.biopsych.2014.01.08 PubMed
69. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-Analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73(1):81-86. doi:10.408/JCP.10r06710 PubMed
70. Hirashima F, Parow AM, Stoll AL, et al. Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry. 2004;161(10):1922-1924. doi:10.176/ajp.161.10.192 PubMed
71. Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry. 2005;66(6):726-729. doi:10.408/JCP.v6n0608 PubMed
72. Sagduyu K, Dokucu ME, Eddy BA, et al. Omega-3 fatty acids decreased irritability of patients with bipolar disorder in an add-on, open label study. Nutr J. 2005;4(1):6. doi:10.186/1475-2891-4-6 PubMed
73. Wozniak J, Biederman J, Mick E, et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol. 2007;17(6-7):440-447. doi:10.1016/j.euroneuro.206.1.06 PubMed
74. Clayton EH, Hanstock TL, Hirneth SJ, et al. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr. 2009;63(8):1037-1040. doi:10.1038/ejcn.208.81 PubMed
75. Stoll AL, Severus WE, Freeman MP, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56(5):407-412. doi:10.101/archpsyc.56.5.407 PubMed
76. Chiu CC, Huang SY, Chen CC, et al. Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry. 2005;66(12):1613-1614. doi:10.408/JCP.v6n1219b PubMed
77. Keck PE Jr., Mintz J, McElroy SL, et al. Doubleblind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry. 2006;60(9):1020-1022. doi:10.1016/j.biopsych.206.03.056 PubMed
78. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebocontrolled study. Br J Psychiatry. 2006;188(1):46-50. doi:10.192/bjp.18.1.46 PubMed
79. Frangou S, Lewis M, Wollard J, et al. Preliminary in vivo evidence of increased N-Acetylaspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J Psychopharmacol. 2007;21(4):435-439. doi:10.17/0269810606787 PubMed
80. Gracious BL, Chirieac MC, Costescu S, et al. Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord. 2010;12(2):142-154. doi:10.1/j.139-5618.2010.079.x PubMed
81. Murphy BL, Stoll AL, Harris PQ, et al. Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol. 2012;32(5):699-703. doi:10.1097/JCP.0b013e31826854c PubMed
82. Rapoport SI. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease. Prostaglandins Leukot Essent Fatty Acids. 2008;79(3-5):153-156. doi:10.1016/j.plefa.208.09.010 PubMed
83. Ryan VH, Primiani CT, Rao JS, et al. Coordination of gene expression of arachidonic and docosahexaenoic acid cascade enzymes during human brain development and aging. PLoS ONE. 2014;9(6):e100858. doi:10.1371/journal.pone.010858 PubMed
84. Blasbalg TL, Hibbeln JR, Ramsden CE, et al. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr. 2011;93(5):950-962. doi:10.3945/ajcn.10.0643 PubMed
85. Ramsden CE, Faurot KR, Zamora D, et al. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: a randomized trial. Pain. 2013;154(11):2441-2451. doi:10.1016/j.pain.2013.07.028 PubMed
86. Baptista T, Uzcátegui E, Arapé Y, et al. Migraine life-time prevalence in mental disorders: concurrent comparisons with first-degree relatives and the general population. Invest Clin. 2012;53(1):38-51. PubMed
87. Ortiz A, Cervantes P, Zlotnik G, et al. Crossprevalence of migraine and bipolar disorder. Bipolar Disord. 2010;12(4):397-403. doi:10.1/j.139-5618.2010.0832.x PubMed
88. Dilsaver SC, Benazzi F, Oedegaard KJ, et al. Migraine headache in affectively ill Latino adults of Mexican American origin is associated with bipolarity. Prim Care Companion J Clin Psychiatry. 2009;11(6):302-306. doi:10.408/PC.08m0728 PubMed
89. McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006;57(8):1140-1144. doi:10.176/ps.206.57.8.140 PubMed
90. McIntyre RS, Konarski JZ, Wilkins K, et al. The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey. Headache. 2006;46(6):973-982. doi:10.1/j.1526-4610.206.0469.x PubMed
91. Fasmer OB. The prevalence of migraine in patients with bipolar and unipolar affective disorders. Cephalalgia. 2001;21(9):894-899. doi:10.1046/j.1468-2982.201.0279.x PubMed
92. Fasmer OB, Oedegaard KJ. Clinical characteristics of patients with major affective disorders and comorbid migraine. World J Biol Psychiatry. 2001;2(3):149-155. doi:10.3109/1562970109026801 PubMed
93. Saunders EF, Nazir R, Kamali M, et al. Gender differences, clinical correlates, and longitudinal outcome of bipolar disorder with comorbid migraine. J Clin Psychiatry. 2014;75(5):512-519. doi:10.408/JCP.13m08623 PubMed
94. Antonova M, Wienecke T, Olesen J, et al. Prostaglandin E(2) induces immediate migraine-like attack in migraine patients without aura. Cephalalgia. 2012;32(11):822-833. doi:10.17/03102412451360 PubMed
95. Ramsden CE, Mann JD, Faurot KR, et al. Low omega-6 vs low omega-6 plus high omega-3 dietary intervention for chronic daily headache: protocol for a randomized clinical trial. Trials. 2011;12(1):97. doi:10.186/1745-6215-12-97 PubMed
96. Moskowitz MA, Buzzi MG. Migraine general aspects. Handb Clin Neurol. 2010;97:253-266. doi:10.1016/S072-9752(10)97021-8 PubMed
97. Buzzi MG, Moskowitz MA. The pathophysiology of migraine: year 2005. J Headache Pain. 2005;6(3):105-111. doi:10.107/s10194-05-0165-2 PubMed
98. Buzzi MG, Moskowitz MA. The trigeminovascular system and migraine. Pathol Biol (Paris). 1992;40(4):313-317. PubMed
99. Geddes JR, Goodwin GM, Rendell J, et al; BALANCE investigators and collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385-395. doi:10.1016/S0140-6736(09)61828-6 PubMed
100. Linde M, Mulleners WM, Chronicle EP, et al. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6(6):CD010611. PubMed
101. Lampl C, Katsarava Z, Diener HC, et al. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry. 2005;76(12):1730-1732. doi:10.136/jnp.205.063750 PubMed
102. Ramsden CE, Ringel A, Feldstein AE, et al. Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. Prostaglandins Leukot Essent Fatty Acids. 2012;87(4-5):135-141. doi:10.1016/j.plefa.2012.08.04 PubMed
103. MacIntosh BA, Ramsden CE, Faurot KR, et al. Low-n-6 and low-n-6 plus high-n-3 diets for use in clinical research. Br J Nutr. 2013;110(3):559-568. doi:10.1017/S071451205181 PubMed